title: INCIDENCE OF SUSTAINED OCULAR HYPERTENSION USING PREPACKAGED VERSUS FRESHLY PREPARED INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
abstract: OBJECTIVE
  To compare the incidence of sustained ocular hypertension (OHT) after intravitreal injections of prepackaged versus freshly prepared bevacizumab monotherapy for the treatment of neovascular age-related macular degeneration.
  
  
  METHODS
  Charts of 1,216 patients with neovascular age-related macular degeneration receiving intravitreal bevacizumab monotherapy at 2 retina practices using different preparations of bevacizumab between January 1, 2009, and December 31, 2011, were reviewed. Primary outcome was incidence of sustained OHT, defined as intraocular pressure > 25 mmHg with an increase ≥ 6 from baseline on ≥ 2 consecutive visits or requiring treatment.
  
  
  RESULTS
  A total of 6,479 injections in 740 eyes of 634 patients were included and 14 eyes (0.81% incidence per eye-year) developed sustained OHT. For eyes receiving prepackaged bevacizumab, 10 of 339 eyes (1.39% incidence per eye-year) developed sustained OHT compared with 4 of 401 eyes (0.39% incidence per eye-year) receiving freshly prepared bevacizumab, giving an incidence rate ratio of 3.55 (95% confidence interval, 0.93-13.49; P = 0.063). All eyes that developed sustained OHT achieved intraocular pressure control with observation or topical therapy alone.
  
  
  CONCLUSIONS
  Incidence of sustained OHT after intravitreal bevacizumab is low. We found a trend toward higher rates of sustained OHT with prepackaged bevacizumab although this difference was not statistically or clinically significant.
authors.affiliation: *Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania; †Emory Eye Center, Emory University, Atlanta, Georgia; ‡Division of Biostatistics, Jefferson Medical College, Philadelphia, Pennsylvania; and §USC Eye Institute, University of Southern California, Los Angeles, California.
authors.forename: Philip P
authors.initials: PP
authors.lastname: Storey
authors.forename: Vincent
authors.initials: V
authors.lastname: Ho
authors.forename: Steven
authors.initials: S
authors.lastname: Yeh
authors.forename: Sahitya
authors.initials: S
authors.lastname: Reddy
authors.forename: Natalie Hsiao
authors.initials: NH
authors.lastname: Fang-Yen
authors.forename: Edward
authors.initials: E
authors.lastname: Pequignot
authors.forename: Benjamin E
authors.initials: BE
authors.lastname: Leiby
authors.forename: Mitchell
authors.initials: M
authors.lastname: Fineman
authors.forename: Sunir
authors.initials: S
authors.lastname: Garg
authors.forename: G Baker
authors.initials: GB
authors.lastname: Hubbard
authors.forename: Jason
authors.initials: J
authors.lastname: Hsu
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D004339:Drug Compounding; D004349:Drug Packaging; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007429:Intraocular Pressure / Q000187:drug effects; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000139:chemically induced / Q000453:epidemiology*; D012307:Risk Factors; D014065:Tonometry, Ocular; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D057135:Wet Macular Degeneration / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab